The FDA announced Breakthrough Therapy Designation (BTD) for acalabrutinib (Calquence) as a single agent to treat chronic lymphocytic leukemia (CLL)
On Jan. 22, 2018, Celgene announced they had acquired Juno Therapeutics. Juno’s CAR-T, JCAR017, looks very promising in CLL and is very similar to the CAR-T that I took in my successful clinical trial. One year later, on Jan. 3, 2019, Bristol-Myers Squibb announced plans to acquire Celgene. Here is a link to press coverage: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-acquire-celgene-create-premier-innovative
Related posts
